These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38980402)
21. Ten-year trends in hospitalizations related to cocaine abuse in France. Eiden C; Roy S; Malafaye N; Lehmann M; Peyrière H Fundam Clin Pharmacol; 2022 Dec; 36(6):1128-1132. PubMed ID: 35801616 [TBL] [Abstract][Full Text] [Related]
22. [Twenty-five years of the French Addictovigilance Network (FAN)]. Micallef J; Mallaret M Therapie; 2016 Sep; 71(4):375-8. PubMed ID: 27296806 [TBL] [Abstract][Full Text] [Related]
23. Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution. Dupui M; Micallef J; Lapeyre-Mestre M Therapie; 2019 Apr; 74(2):307-314. PubMed ID: 30798951 [TBL] [Abstract][Full Text] [Related]
24. [From psychoactive medicines to addictovigilance in French Public Health Code (1990-2017)]. Baumevieille M; Perri-Plandé J; Miremont-Salamé G; Daveluy A; Haramburu F Therapie; 2019 Jun; 74(3):375-382. PubMed ID: 30193805 [TBL] [Abstract][Full Text] [Related]
25. [Acting out and psychoactive substances: alcohol, drugs, illicit substances]. Gillet C; Polard E; Mauduit N; Allain H Encephale; 2001; 27(4):351-9. PubMed ID: 11686057 [TBL] [Abstract][Full Text] [Related]
26. Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network. Eiden C; Leone-Burgos S; Serre A; Carton L; Gerardin M; Le Boisselier R; Gibaja V; Monzon E; Fouilhe N; Boucher A; Peyriere H; Fundam Clin Pharmacol; 2018 Dec; 32(6):654-662. PubMed ID: 29956843 [TBL] [Abstract][Full Text] [Related]
27. [Psychoactive substances use in Réunion Island and Mayotte, French departments in Indian Ocean]. Daveluy A; Haramburu F Therapie; 2018 Oct; 73(5):419-427. PubMed ID: 29773359 [TBL] [Abstract][Full Text] [Related]
28. Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: Insights of the annual cross sectional OPPIDUM survey. Blayac L; Ponte C; Lavaud M; Micallef J; Lapeyre-Mestre M Therapie; 2023; 78(2):201-211. PubMed ID: 36283856 [TBL] [Abstract][Full Text] [Related]
29. Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases: Illustration From the Experience of the French Addictovigilance Network. Soeiro T; Lacroix C; Pradel V; Lapeyre-Mestre M; Micallef J Front Psychiatry; 2021; 12():640120. PubMed ID: 34079478 [TBL] [Abstract][Full Text] [Related]
30. Snapshot of narcotic drugs and psychoactive substances in Kuwait: analysis of illicit drugs use in Kuwait from 2015 to 2018. Al-Matrouk A; Al-Hasan M; Naqi H; Al-Abkal N; Mohammed H; Haider M; Al-Shammeri D; Bojbarah H BMC Public Health; 2021 Apr; 21(1):671. PubMed ID: 33827491 [TBL] [Abstract][Full Text] [Related]
32. Disparities in Use/Misuse of Specific Illicit and Prescription Drugs among Sexual Minority Adults in a National Sample. Schuler MS; Collins RL; Ramchand R Subst Use Misuse; 2022; 57(3):461-471. PubMed ID: 35067155 [No Abstract] [Full Text] [Related]
33. An overview of the use of psychoactive substances among students at the University of Lille during the COVID-19 health crisis: Results of the PETRA study. Carton L; Bastien A; Chérot N; Caron C; Deheul S; Cottencin O; Gautier S; Moreau-Crépeaux S; Dondaine T; Bordet R Dialogues Clin Neurosci; 2023 Dec; 25(1):101-111. PubMed ID: 37837439 [TBL] [Abstract][Full Text] [Related]
34. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network. Gandolfo P; Soeiro T; Jouve É; Revol B; Daveluy A; Bertin C; Eiden C; Gibaja V; Chaouachi L; Pérault-Pochat MC; Chevallier C; Aquizérate A; Le Boisselier R; Carton L; Lapeyre-Mestre M; Frauger É; Lacroix C; Micallef J Fundam Clin Pharmacol; 2024 Oct; 38(5):978-987. PubMed ID: 38372190 [TBL] [Abstract][Full Text] [Related]
35. [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network]. Frauger E; Pochard L; Boucherie Q; Giocanti A; Chevallier C; Daveluy A; Gibaja V; Caous AS; Eiden C; Authier N; Le Boisselier R; Guerlais M; Jouanjus É; Lepelley M; Pizzoglio V; Pain S; Richard N; Micallef J; Therapie; 2017 Sep; 72(4):491-501. PubMed ID: 28343650 [TBL] [Abstract][Full Text] [Related]
36. [Cathinones use in Paris]. Batisse A; Grégoire M; Marillier M; Fortias M; Djezzar S Encephale; 2016 Aug; 42(4):354-60. PubMed ID: 26847479 [TBL] [Abstract][Full Text] [Related]
37. [Reimbursement of opiate substitution drugs to militaries in 2007]. d'Argouges F; Desjeux G; Marsan P; Thevenin-Garron V Encephale; 2012 Sep; 38(4):304-9. PubMed ID: 22980471 [TBL] [Abstract][Full Text] [Related]
38. Erratum: Nitrous oxide: a unique official French addictovigilance national survey. Frontiers Production Office Front Public Health; 2023; 11():1235720. PubMed ID: 37469693 [TBL] [Abstract][Full Text] [Related]
39. Substance misuse in patients who have comorbid chronic pain in a clinical population receiving methadone maintenance therapy for the treatment of opioid dependence. Higgins C; Smith BH; Matthews K Drug Alcohol Depend; 2018 Dec; 193():131-136. PubMed ID: 30368067 [TBL] [Abstract][Full Text] [Related]